Melatonina LEK-AM

Quick links

Choose a section

Quick links to important sections

Advertisements

Melatonina LEK-AM

Advertisements
Advertisements

Overview of Melatonina LEK-AM

Quick Facts

Property Description
Active ingredient Melatonin (N-acetyl-5-methoxytryptamine)
Form Oral Tablet
Pharmacological class Melatonin Receptor Agonist, Chronobiotic
Common purpose Synchronization of the Sleep-Wake Cycle
Origin Synthetically Produced Equivalent

What Type of Medicine is Melatonina LEK-AM? (Definition and Classification)

Melatonina LEK-AM is an oral tablet preparation classified pharmacologically as a melatonin receptor agonist and a chronobiotic. It is a single-ingredient pharmaceutical product, originating from the Polish manufacturer LEK-AM, and is administered via the oral route.

The medicine's classification as a chronobiotic indicates a primary function focused on regulating the sleep-wake cycle. This mechanism ensures the product works by adjusting the body's internal clock, differentiating its action from traditional generalized sedative effects. The preparation is utilized specifically to address issues where the timing of sleep is the primary difficulty.

What is the Composition of Melatonina LEK-AM? (Ingredient Identity and Origin)

The active ingredient in the preparation is the substance Melatonin, which carries the systematic chemical name N-acetyl-5-methoxytryptamine. Melatonin is a tryptamine derivative present in the tablet alongside necessary solid pharmaceutical excipients.

While chemically identical to the hormone naturally produced by the brain's pineal gland, the compound used in Melatonina LEK-AM is a synthetically produced equivalent. This ensures a standardized and consistent dose, a factor critical for reliable chronobiotic action. This approach allows the preparation to reliably supplement or substitute the body's own hormonal output, which can be insufficient or mistimed.

General Purpose of Melatonin: Regulating the Sleep-Wake Cycle

The general purpose of Melatonina LEK-AM is to facilitate the body's natural signal to initiate sleep, which is accomplished by stimulating MT1 and MT2 receptors to communicate "nighttime" to the central nervous system. Exogenous melatonin plays a role in normalizing the sleep-wake rhythm.

The primary function of the tablet is to help align the sleep-wake pattern with the desired schedule, such as stabilizing the sleep cycle following travel across multiple time zones. By providing this consistent hormonal cue, the preparation assists individuals whose own melatonin production is deficient or suppressed, thereby facilitating the natural, controlled regulation of their circadian rhythm.

Regulatory References

  1. Melatonin: What You Need To Know (NIH NCCIH)
Advertisements

What side effects are possible with Melatonina LEK-AM?

The safety profile for Melatonina LEK-AM is documented through regulatory sources, with adverse reactions classified by the frequency of occurrence. The majority of reported side effects are considered mild to moderate.

Reported Side Effects by Frequency

Frequency Category Examples of Adverse Reactions (by System-Organ Class)
Common (1 to 10 in 100 people) Headache, somnolence (drowsiness/sleepiness), asthenia, confusion, sedation.
Uncommon (1 to 10 in 1,000 people) Irritability, nervousness, restlessness, anxiety, abdominal pain, dry mouth, nausea, pruritus (itching), rash, weight increased, hypertension.
Rare (1 to 10 in 10,000 people) Leucopenia, thrombocytopenia, aggressive behaviour, syncope (fainting), blurred vision, palpitations, vomiting, haematuria, priapism, and gynecomastia.
Not Known (Cannot be estimated) Hypersensitivity reaction, hyperglycaemia, tongue oedema, galactorrhoea.

Safety Considerations and Limitations

Special Caution: This medicine is not recommended for use in patients with autoimmune diseases, liver impairment, or during pregnancy or breastfeeding due to insufficient clinical data; effective contraception should be used by women of childbearing potential. Caution should also be exercised in patients with kidney dysfunction, depression, or epilepsy, as there are reports of increased seizure frequency in some populations.

Restrictions: The medicine may cause drowsiness and reduce concentration. Patients are advised not to drive or operate machinery after use. Alcohol consumption should be avoided as it may diminish the medicine's effect on sleep and increase the risk of adverse reactions.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Melatonina LEK-AM overdose defines manifestations primarily as transient central nervous system depression. Documented presentations include excessive drowsiness, dizziness, fatigue, confusion, and headache. Gastrointestinal symptoms are also noted, such as nausea, diarrhoea, and abdominal cramps. Less common signs that may be observed are mild hypothermia and changes in cardiovascular status, including hypotension or tachycardia.


The management protocol is based on the fact that no specific antidote is known. Treatment is limited to general supportive measures and symptomatic care to maintain stability, with procedural steps like gastric lavage considered based on clinical necessity. The regulatory guidance mandates that immediate emergency medical attention must be sought if severe manifestations occur, specifically citing seizures, marked difficulty breathing, or loss of consciousness. Furthermore, official surveillance reports indicate that young children (le5 years) are at a higher risk for severe outcomes and hospitalization following unintentional high-dose ingestion. All overdose effects are generally expected to clear within 12 hours as the body processes the active substance.

Advertisements

Therapeutic Uses of Melatonina LEK-AM

What Melatonina LEK-AM Treats: Main Uses and Benefits

The primary role of this medication is to provide supportive relief for symptoms associated with sleep and circadian rhythm disturbances. This medicine is commonly used to help with symptoms that interfere with daily functioning. This is relevant for easing certain distressing symptoms of primary insomnia (difficulty falling asleep) and for managing conditions associated with acute or disruptive episodes, such as jet lag.

This medication is applied across domains where additional symptomatic support is needed. It supports patients during episodes of heightened discomfort, and is used for managing symptoms that interfere with daily comfort. It is generally applied in addressing Wood conditions characterized by periods of heightened symptoms, offering the patient the benefit of establishing a more regular and predictable sleep pattern. This contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Disrupted Sleep
This medication supports individuals dealing with symptoms related to systemic imbalance, such as when adapting to new time zones or dealing with shift work.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Melatonina LEK-AM?

The use of this medicine is strictly governed by regulatory criteria outlining approved populations and specific health-based restrictions documented in official product information.

Populations Allowed The medicine is authorized for Adults aged 18 and over seeking short-term relief for jet lag or managing circadian rhythm disturbances. Older adults are included within the standard adult eligibility criteria.

Absolute Prohibitions (Contraindications) Use is contraindicated if a patient has a known hypersensitivity to melatonin or any excipient in the tablet. Use is also restricted from concomitant use with alcohol.

Restrictions and Cautions Use is not recommended for several populations:

  • Children and Adolescents (under 18 years) due to safety and efficacy not being established.
  • Pregnancy and Lactation due to insufficient clinical data.
  • Patients with moderate or severe hepatic impairment (liver dysfunction) or severe renal impairment (kidney dysfunction).
  • Individuals with autoimmune diseases.
  • Caution is advised for patients with epilepsy and those with non-severe renal impairment or impaired glucose control.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Melatonin is structured around pharmacokinetic and pharmacodynamic interactions. All interaction information is strictly based on authoritative government labeling.

  • Avoided/Contraindicated Combinations: Co-administration with the strong CYP1A2 inhibitor Fluvoxamine is officially discouraged due to a documented substantial increase in Melatonin systemic exposure. Concomitant use with Benzodiazepine-related hypnotics (e.g., Zolpidem) should be avoided due to the enhancement of sedative properties and increased cognitive impairment. Similarly, the combination with Vitamin K Antagonists (e.g., Warfarin) is avoided due to the risk of unpredictable alteration in blood clotting status.

  • Exposure Modification: The metabolism of Melatonin is primarily mediated by the CYP1A2 enzyme. Inhibitors such as Cimetidine, Oestrogens (e.g., from contraceptives), and certain Quinolone antibiotics are documented to increase Melatonin plasma concentrations. Conversely, inducers like Rifampicin, Carbamazepine, and Cigarette Smoking may reduce Melatonin levels.

  • Substance and Timing Constraints: Alcohol should not be consumed concurrently, as it reduces the effect on sleep. The regulatory label includes specific timing rules with food: the tablet must be separated from food intake by at least two hours to prevent enhanced exposure and potential impact on blood glucose control. Administration of NSAIDs in the evening, and Beta-blockers at night, should be avoided as both are associated with suppressing the body's natural melatonin rhythm.

  • Population Notes: Patients with documented hepatic impairment exhibit markedly elevated Melatonin levels due to decreased clearance.

Advertisements

Mechanism of Action

How Melatonina LEK-AM Works: Mechanism of Action

The molecule's mechanism is defined by its role as a chronobiotic, characterized by the activation of specific central receptors that adjust the intrinsic rhythm.


Targeted Agonism of mathbfMT1 and mathbfMT2 Receptors

The primary mechanism involves agonism (activation) of the mathbfMT1 and mathbfMT2 receptors, which are concentrated in the brain's Suprachiasmatic Nucleus (SCN), the body's master clock. This molecular action initiates an inhibitory signaling cascade, leading to a reduction in SCN electrical activity and attenuating the electrical firing of SCN neurons.


Modulating the Central Clock and Circadian Rhythm

Activation of these receptors leads to the suppression of the second messenger cAMP, which fundamentally alters the excitability of SCN neurons. The MT1 action increases the likelihood of transitioning to the sleep phase, while MT2 activation mediates the phase shift, or temporal alteration, of the sleep-wake cycle. The action is highly dependent on the timing of administration relative to the existing circadian phase.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Melatonina LEK-AM — Administration Guidelines

This section describes the standardized instructions for use.

Administration Scope

Field Instruction
Route of administration Oral use (swallowed by mouth).
Dosing schedule The standard single dose is 3 mg once daily, typically for short-term use. A maximum dose of 6 mg may be applied if the standard dose is insufficient.
Timing in relation to meals The tablet must be taken with a separation of approximately two hours from any meal consumed before or after administration.
Preparation requirements The tablet must be swallowed whole with fluid and is not to be crushed or chewed.
Age-group administration rules No specific dose reduction is required for older adults. The medicine is not recommended for patients with severe hepatic or severe renal impairment.
Missed-dose rules If a dose is missed at the prescribed bedtime, it may be taken later in the night but no later than 04:00 hr; double doses are not permitted to compensate for a forgotten dose.
Special procedural conditions The timing of administration must be within the window of 20:00 hr to 04:00 hr at the destination, and the individual must be able to obtain at least 6 to 8 hours of uninterrupted sleep after taking the dose.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily
Use-context constraints Strict time-of-day; Post-administration sleep availability; Distance from food intake; Short-term course duration (e.g., maximum of 5 days).

Resulting Procedural Structure

Step sequence:

  • Swallow the prescribed dose as a whole tablet with fluid.
  • Ensure the dose is taken at a specified time, typically the habitual bedtime, within the window of 20:00 hr to 04:00 hr.
  • Maintain a distance of two hours from any major meal.
  • Ensure a minimum of 6 to 8 hours of uninterrupted rest is possible after administration.
  • Limit the duration of use to short, time-bound courses (e.g., a maximum of 5 days or 16 treatment periods per year).

Connection to the overall use protocol: The administration protocol is defined by timing, frequency, and duration to facilitate its intended chronobiotic function. The medicine is intended for once-daily oral use under specific conditions, which are designed to support a standardized and controlled pattern of administration.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Melatonina LEK-AM

Evidence for Use in Primary Insomnia

The research for this medicine was studied for conditions characterized by fluctuating or episodic manifestations of difficulty falling asleep, particularly in older adults. The clinical evidence primarily consists of short-term Randomized Controlled Trials (RCTs), where the medicine was evaluated in specific groups and compared against an inactive substance (placebo). This research is further synthesized in Systematic Reviews and Meta-analyses.

Researchers examined several outcomes related to systemic or functional imbalance, such as the time taken to fall asleep (sleep onset latency) and the overall subjective quality of sleep (using patient-reported outcomes describing perceived discomfort). Within the studied populations, findings describe patterns observed in the studies regarding measured changes in both the time it took to fall asleep and the self-reported sleep quality. However, these findings describe group patterns, not personal outcomes, and the research provides context but not individual predictions.

Evidence for Use in Jet Lag

Research was studied for conditions associated with acute or disruptive episodes of jet lag experienced after crossing several time zones. The studies explored outcomes describing episodic or acute changes associated with this condition, such as daytime sleepiness and the ability to re-establish the normal sleep-wake cycle upon arrival.

These trials monitored self-reported jet lag severity and the time taken to fall asleep during the adjustment period. Aggregated data show patterns related to measured differences in the overall severity of jet lag symptoms across the first few days of adaptation.

Research Focus on Specific Populations

This section details the populations observed in the key studies, outlining the research that was evaluated in older adults (aged 55 years and over) with primary insomnia, and adult air travelers experiencing conditions associated with acute or disruptive episodes of jet lag. The results apply only to the populations studied under the specific conditions of the trials.

Long-Term Evidence and Follow-Up Duration

For both the insomnia and jet lag research, follow-up durations were limited, typically lasting only a few weeks for insomnia and a few days for jet lag. Consequently, there is limited information for long-term outcomes that may arise from using the medicine over many months. Long-term effects are not fully established regarding whether the observed patterns are maintained over extended periods or the durability of the observed patterns after the study period ends.

Evidence Gaps and Areas of Uncertainty

While research contributes to the broader evidence landscape, certainty remains low in several key areas: Comparative evidence is lacking, meaning there is limited information from studies that directly compare this medicine to other available treatments. The durability of efficacy and maintenance of outcomes, as follow-up durations were limited in the key studies.

Key Studies & References Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Melatonina LEK-AM (FAQ)

Q: Is Melatonina LEK-AM meant for long-term or short-term use?

A: Official information indicates that this medicine is primarily studied and licensed for short-term use for specific conditions. For jet lag, for example, the duration of use is generally limited to only a few days. For primary sleep rhythm disorders, treatment is typically reviewed or limited after about 13 weeks to assess the need for continued use.


Q: How long does it typically take to start feeling the effects of Melatonina LEK-AM?

A: Official documents state that the effects can be observed gradually, depending on the condition being addressed. For certain rhythm disorders, changes have been described in regulatory documents as being observed over the first few weeks of treatment. The timing of administration is often strictly controlled to coincide with the onset of the desired effect, usually around the habitual bedtime.


Q: Are there different strengths of Melatonina LEK-AM available?

A: Melatonina LEK-AM is available in different tablet strengths, depending on the specific country's regulatory approval. These generally include formulations such as 1 mg, 3 mg, and 5 mg tablets. The authorized dose for an individual depends on the specific regulatory guidelines and the licensed indication.


Q: Is there a certain time of day Melatonina LEK-AM is typically used?

A: Yes, the timing of administration is a specific condition of use documented in official instructions. For jet lag, the dose must be taken within a strict window, typically between 8:00 PM and 4:00 AM in the destination time zone. For other rhythm disorders, it is generally advised to take the medicine around the habitual bedtime.


Q: How does the action of Melatonina LEK-AM differ from sedative-hypnotics?

A: Official sources classify Melatonina LEK-AM as a chronobiotic, which means its primary function is to adjust or synchronize the body's internal clock (circadian rhythm) by acting on specific brain receptors. This mechanism differs from traditional sedative-hypnotics, which generally act as generalized central nervous system depressants to induce sedation.


Q: Does Melatonina LEK-AM help with falling asleep or staying asleep, or both?

A: Clinical studies for licensed uses examined outcomes related to both the time taken to fall asleep, known as sleep latency, and the overall self-reported quality of sleep. Official research examined outcomes related to both the time taken to fall asleep (initiation) and the overall subjective quality of rest.


Q: Are there any specific driving or machine operating considerations while using Melatonina LEK-AM?

A: Yes, official safety documents advise patients not to drive or operate complex machinery after taking the medicine. This warning is based on the fact that the medicine may cause drowsiness and a reduction in concentration.


Q: How does the recommended use for jet lag differ from the use for primary insomnia?

A: The official uses differ primarily in the duration and administration protocol. Use for jet lag is a short-term, time-limited course, such as a maximum of five days. In contrast, the licensed use for primary insomnia in older adults can extend for a longer period, such as up to 13 weeks.


Q: What is the difference between immediate-release and extended-release formulations, if any exist for Melatonina LEK-AM?

A: Melatonina LEK-AM is an immediate-release oral tablet, meaning the active substance is quickly absorbed. Other melatonin preparations may be available as prolonged-release tablets, which are designed to release the medicine gradually over the course of the night to maintain levels during sleep.


Q: Is it normal to have vivid dreams while taking Melatonina LEK-AM?

A: While not common, the official safety information for melatonin products lists abnormal dreams and nightmares as possible uncommon side effects. Unexpected changes to sleep patterns are typically noted as reasons to seek professional guidance.


Q: How quickly does Melatonina LEK-AM leave the body after it's taken?

A: According to the regulatory pharmacokinetic profile, the active ingredient, melatonin, has a relatively short half-life in the body. This means that after absorption, the substance is quickly broken down and eliminated, typically with a half-life in the range of 3.5 to 4 hours.


Q: Why is Melatonina LEK-AM sometimes used for blind people?

A: Regulatory documents indicate that one of the licensed uses for this medicine is as a supportive treatment for disorders of the daily sleep-wake rhythm in blind patients. This population may use it to help regulate their circadian rhythm.


Q: Does Melatonina LEK-AM affect mood or memory?

A: The official safety documentation lists some effects on the nervous system and mood as possible side effects. Uncommon or rare reported side effects include depressed mood, anxiety, irritability, and memory impairment.


Q: Does Melatonina LEK-AM affect fertility or hormones?

A: Information in the regulatory documents on the effect of the medicine on human fertility is limited or not established. The medicine is not recommended for women who are or may become pregnant due to insufficient data. The safety documentation also lists rare endocrine side effects such as gynecomastia.


Q: Are there any known drug interactions with common anti-depressants?

A: Official documentation notes a few specific interactions. The antidepressant Fluvoxamine is documented to substantially increase the amount of melatonin in the body and should be avoided. Other antidepressants, such as Amitriptyline, are cautioned against due to the potential for increasing the medicine's sedative effects.


Q: Does using Melatonina LEK-AM impact the body's own production of melatonin?

A: Studies backed by regulatory bodies suggest that the use of the medicine does not suppress the body's natural (endogenous) production of melatonin. This finding comes from official research, including studies on prolonged-release formulations.


Q: Is Melatonina LEK-AM gluten-free or lactose-free?

A: The excipients (inactive ingredients) in Melatonina LEK-AM are listed in the official documents, including microcrystalline cellulose and magnesium stearate. The product is not explicitly labeled as lactose-free, and some similar formulations contain lactose, which is a fact often noted in official leaflets.


Q: Is Melatonina LEK-AM used for shifts workers' sleep problems?

A: Yes, the official regulatory information indicates that this medicine is used as a supportive treatment for sleep disorders related to sleep-wake rhythm disorders, and specifically includes those related to shift work.


Q: What information is available regarding the effect of Melatonina LEK-AM on body weight?

A: The official safety documentation lists weight increased as a possible side effect. This is classified as an uncommon effect, meaning it has been reported to affect between 1 and 10 in every 1,000 people.


Q: What is the meaning of 'LEK-AM' in the drug name?

A: The 'LEK-AM' part of the drug name refers to the Pharmaceutical Company LEK-AM Sp. z o.o., which is the company that holds the marketing authorisation or is the manufacturer of the product in some regions.


Q: Does the efficacy of Melatonina LEK-AM change over a long period of use?

A: Research evaluating some prolonged-release melatonin formulations over extended periods, up to one year, has not demonstrated a reduction in the effect on total sleep time. However, long-term studies for all formulations are considered limited, and the durability of effects remains an area of uncertainty.


Q: What should be done if an allergic reaction is suspected after taking Melatonina LEK-AM?

A: The medicine is officially contraindicated if a patient has a known hypersensitivity (severe allergic reaction) to the active substance or any other ingredients. In the event a serious reaction is suspected, professional medical assistance should be sought, and the adverse event should be reported via official monitoring schemes.


Q: What is the difference between insomnia and primary insomnia in the context of Melatonina LEK-AM?

A: The medicine is specifically licensed for use in primary insomnia characterized by poor quality of sleep in older adults. Primary insomnia is generally defined as sleep difficulty that is not caused by another medical condition, psychiatric disorder, or external environmental factors.


Q: Are the safety profiles different for long-term versus short-term use?

A: Official research focuses primarily on short-term safety, such as for periods of 13 weeks. While longer studies have been conducted, the available information on the safety profile's durability over many months or years is considered limited, and long-term effects are not fully established.

Advertisements

How should Melatonina LEK-AM be stored and disposed of?

How to Store and Dispose of Melatonina LEK-AM?

The official labeled requirements for Melatonina LEK-AM strictly define its required storage environment and handling.

Required Storage Conditions

  • Labeled storage temperature requirements: The tablets must be stored at a temperature below 25 C.
  • Child-protection storage requirements: The medicine must be kept out of the sight and reach of children.

Stability and Disposal

  • Storage-context constraints: The product must not be used after the expiry date stated on the packaging.
  • Disposal instructions (as documented in government sources): Regulatory documents do not provide explicit instructions for discarding unused or expired Melatonina LEK-AM, such as specific rules against flushing or disposal in household waste. Disposal should follow general local pharmaceutical waste guidelines.

Connection to the overall storage/disposal profile: Regulatory documents define the required storage environment by setting a maximum temperature and mandate a critical safety instruction to protect the medicine from children. The product's stability is tied to the printed expiry date, past which use is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melatonina LEK-AM found in:

A-Z Index: